Brief: Cantargia Reports Positive Results For CAN10 Antibody In Preclinical Systemic Sclerosis Model
13/12/2021 13:52
Dec 13 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA REPORTS POSITIVE RESULTS FOR CAN10 ANTIBODY IN
PRECLINICAL SYSTEMIC SCLEROSIS MODEL
* CANTARGIA AB- LEVELS OF SEVERAL BIOMARKERS AFFECTED IN
SYSTEMIC
SCLEROSIS PATIENTS NORMALIZED BY CAN10 ANTIBODY IN SYSTEMIC
SCLEROSIS DISEASE MODEL
* CANTARGIA AB- RESULTS SUPPORTING CLINICAL DEVELOPMENT OF
CAN10
IN SYSTEMIC SCLEROSIS PLANNED TO BE PRESENTED AT A SCIENTIFIC
CONFERENCE DURING Q1 2022
Source text for Eikon: ID:nPref64Spa
Further company coverage: CANTA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML